Avita Medical Granted European Patent Covering Platform Technology

NORTHRIDGE, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Avita Medical Ltd. (ASX:AVH) (OTCQX:AVMXY), the regenerative medicine company, has been granted European patent EP1357922B1 “Cell Suspension Preparation Technique and Use” by the European Patent Office. The patent covers broad claims related to the preparation of a cell suspension comprised of the patient’s own epithelial cells (autologous suspension), the therapeutic use of the cell suspension and, importantly, a ‘composition of matter’ claim wherein the actual suspension of autologous cells is covered.

Back to news